FDA grants priority review for Roche’s Tecentriq combo sBLA

Roche has received the FDA priority review for its sBLA for adjuvant Tecentriq and Tecentriq Hybreza in combination with chemotherapy for colon cancer. The FDA is anticipated to make its decision on the regimen by 9 October 2026. The submission is supported by data from the Phase III ATOMIC study. Credit: Gorodenkoff / Shutterstock.com. Roche has received the US Food and Drug Administration (FDA) priority review for its supplemental biologics licence application (sBLA) for adjuvant Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) in combination with chemotherapy for colon cancer. The application covers patients with stage III colon cancer characterised…

Source: Pharmaceutical Technology